Print Email

Guideline Development Project — Reviewers Needed

MASCC/ISOO Guidelines for Preventing Cancer-Associated Thrombosis (CAT)

From the Thrombosis in Cancer Leadership Group for the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO)

MASCC’s Hemostasis Study Group is in the process of developing clinical practice guidelines for the prevention of cancer-associated thrombosis. Cancer-associated thrombosis (CAT) is the second most common cause of death in cancer patients (Ambrus JL et al, 1975), with a risk ranging from 8% to 19%, depending on risk factors. Besides mortality, CAT leads to significant morbidity among cancer patients (Khorana AA et al., 2013; Mandala M et al., 2007). To date, MASCC has not released clinical practice guidelines on this issue.

A workshop, “Update on Venous Thromboembolism: Approach and Challenges,” was held at the 2017 Annual Meeting and co-sponsored by the Hemostasis and Education Study Groups. It provided a review of current guidelines and focused on the lack of proper education and materials available for cancer patients. CAT is primarily diagnosed in the ambulatory setting, and in many cases, the only recommended intervention is educating the patient (Lyman GH et al, 2013; Mandala M et al, 2011; National Comprehensive Cancer Network, 2017).

One goal of Study Group guidelines team will be to review the recent literature and to make recommendations or suggestions where applicable for venous thrombosis prevention. A second goal is to develop tools to help educate patients on cancer-associated thrombosis efficiently and effectively. The methods will reflect those of previous MASCC guidelines, and reviewers are needed to assist with literature review and to provide input as we work toward completing the guidelines. MASCC members are invited to join with us in working toward these goals. This is a great opportunity to get involved with the work of the Study Group. If you are interested or would like more information, please contact Taylor Butler ([email protected]).

References
Ambrus JL, Ambrus CM, Mink IB, and Pickren JW. Causes of death in cancer patients. J Med 1975; 6(1): 61-4.
Khorana AA, Dalal M, Lin J, et al. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013; 119: 648-55.
Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guidelines update. J Clin Oncol 2013; 31(17): 2189-205.
Mandala M, Reni M, Cascinu S, et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 2007; 18: 1660-5.
Mandala M, Falanga A, and Rolia F. Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol 2011; 22(Suppl 6): vi85-92.
National Comprehensive Cancer Network. Cancer-associated venous thromboembolic disease. Version 1.2016. Updated 8/1/2017.